. 2015 May 27;7(5):912–921. doi: 10.1080/19420862.2015.1054585

Table 1.

Antibody half-lives predicted in vitro and clinically determined mAb half-lives

mAb	Predicted t_{1/2, β} (±SD )	Clinical t_{1/2, β} (±SD )
Denosumab	849 (±126 )^bcr	768
CDA1	627 (±86 )^br	701 (±181 )^abr
CDB1	577 (±70 )^cdr	579 (±194 )^ac
RAB1	433 (±74 )^abd	473 (±136 )^ac
HCV1	314 (±138 )^abd	279 (±55 )^abr

Superscripts represent significant differences among mAbs within each half-life measurement condition (Predicted or Clinical): ^ap < 0.05 vs. CDA1, ^bp < 0.05 vs. CDB1, ^cp < 0.05 vs. HCV1, ^dp < 0.05 vs Denosumab, ^rp < 0.05 vs. RAB1.